Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress [0.03%]
针对自身免疫性疾病中的新生儿Fc受体：研究进展与管线开发
Torleif Tollefsrud Gjølberg,Simone Mester,Gaia Calamera et al.
Torleif Tollefsrud Gjølberg et al.
Autoimmune diseases are highly prevalent and affect people at all ages, women more often than men. The most prominent immunological manifestation is the production of antibodies directed against self-antigens. In many cases, these antibodie...
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression [0.03%]
实体器官移植中外泌体和免疫激活的影响：免疫抑制的作用
Weicheng Xu,Karin Boer,Dennis A Hesselink et al.
Weicheng Xu et al.
Recent advances in extracellular vesicle (EV) research in organ transplantation have highlighted the crucial role of donor-derived EVs in triggering alloimmune responses, ultimately contributing to transplant rejection. Following transplant...
Miaomiao Chen,Yuli Zhou,Kaicheng Bao et al.
Miaomiao Chen et al.
The development of immune checkpoint inhibitors has revolutionized the treatment of patients with cancer. Targeting the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1(PD-L1) interaction using monoclonal antibodies h...
Comparative Structure Activity Relationship Characterization of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab [0.03%]
可比较的结构活性关系特征化研究关于生物类似药BAT1806/BIIB800和参照托珠单抗
Yujie Liu,Jianhua Xie,Zhuxiang Li et al.
Yujie Liu et al.
Background: BAT1806/BIIB800 (Tofidence™/tocilizumab-bavi), a biosimilar of tocilizumab, demonstrated a high degree of analytical and functional similarity to reference tocilizumab (TCZ) in a comprehensive comparative ana...
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review [0.03%]
通过有针对性的文献审查结果定义可持续的全球生物类似药市场的框架
Joshua A Roth,Victoria W Dayer,Mireia Jofre-Bonet et al.
Joshua A Roth et al.
A biosimilar is a biologic medication that is highly similar to and has no clinically meaningful differences from an existing approved biologic referred to as "reference product." From the introduction of the first biosimilar in 2006 to tod...
Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries [0.03%]
生物类似药政策及其对13个经合组织国家的阿达木单抗、依那西普和英夫利昔单抗市场渗透率的影响：政策综合与描述性分析
Alexander C T Tam,Jasleen Badesha,Daphne P Guh et al.
Alexander C T Tam et al.
Background: Different biosimilar-promoting policies have been implemented worldwide to improve biosimilar uptake and reduce expenditures on costly biologics. ...
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome [0.03%]
可及治疗之路：用于阵发性夜间血红蛋白尿和非典型溶血性尿毒综合症的Eculizumab生物类似药的发展与影响
Jun Ho Jang,Bing Han,Jinah Jung et al.
Jun Ho Jang et al.
Eculizumab, a humanized monoclonal antibody targeting complement C5, is the first approved drug for complement-mediated diseases and indicated to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, myasthenia grav...
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back [0.03%]
NSCLC中免疫检查点抑制剂的原发性和继发性耐药：从临床到基础再回到临床的研究
Annapaola Mariniello,Maxime Borgeaud,Marc Weiner et al.
Annapaola Mariniello et al.
Immunotherapy with checkpoint inhibitors has become the cornerstone of systemic treatment for non-oncogene addicted non-small-cell lung cancer. Despite its pivotal role, a significant proportion of patients-approximately 70-85%-either exhib...
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study [0.03%]
法国成人使用司美格鲁肽(Wegovy)的药物利用情况全国性研究
Nadia Haddy,Hugo Jourdain,David Desplas et al.
Nadia Haddy et al.
Background: Glucagon-like peptide 1 receptor agonists have shown promising results in obesity treatment. In France, semaglutide 2.4-mg (Wegovy) has benefited from an early-access program from July 2022 to September 2023. ...
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects [0.03%]
1型糖尿病的胰岛细胞移植和再生：当前进展与未来前景
Arthur Rech Tondin,Giacomo Lanzoni
Arthur Rech Tondin
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by the destruction of insulin-producing beta cells in the pancreas, leading to insulin deficiency and chronic hyperglycemia. The main current therapeutic strategies for cl...